These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
291 related items for PubMed ID: 24457282
1. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials. Piccolo R, Eitel I, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F. EuroIntervention; 2014 Jan 22; 9(9):1110-20. PubMed ID: 24457282 [Abstract] [Full Text] [Related]
3. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G. Circulation; 2008 Jul 01; 118(1):49-57. PubMed ID: 18559698 [Abstract] [Full Text] [Related]
4. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. De Luca G, Verdoia M, Suryapranata H. Atherosclerosis; 2012 Jun 01; 222(2):426-33. PubMed ID: 22483166 [Abstract] [Full Text] [Related]
6. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Piccolo R, Eitel I, Galasso G, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F. Vascul Pharmacol; 2015 Oct 01; 73():32-7. PubMed ID: 26071862 [Abstract] [Full Text] [Related]
7. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G. Platelets; 2012 Oct 01; 23(4):274-81. PubMed ID: 21988317 [Abstract] [Full Text] [Related]
8. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Thiele H, Wöhrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G, Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators. Am Heart J; 2010 Apr 01; 159(4):547-54. PubMed ID: 20362711 [Abstract] [Full Text] [Related]
9. Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction. Piccolo R, Galasso G, Eitel I, Dominguez-Rodriguez A, Iversen AZ, Gu YL, Abreu-Gonzalez P, de Smet BJ, Esposito G, Windecker S, Thiele H, Piscione F. Am J Cardiol; 2016 Dec 15; 118(12):1798-1804. PubMed ID: 27756477 [Abstract] [Full Text] [Related]
10. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, Déry JP, Gleeton O, Manh-Nguyen C, Noël B, Roy L, Costerousse O, De Larochellière R, EArly Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators. Am J Cardiol; 2010 Jun 01; 105(11):1520-7. PubMed ID: 20494655 [Abstract] [Full Text] [Related]
11. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Wöhrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, Hombach V, Höher M. Circulation; 2003 Apr 15; 107(14):1840-3. PubMed ID: 12682003 [Abstract] [Full Text] [Related]
12. Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient data pooled analysis of randomised studies. Piccolo R, Gu YL, Iversen AZ, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Eitel I, Abreu-Gonzalez P, Thiele H, Piscione F. Heart; 2012 May 24. PubMed ID: 22397943 [Abstract] [Full Text] [Related]
15. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E. J Am Coll Cardiol; 2010 Aug 03; 56(6):463-9. PubMed ID: 20670755 [Abstract] [Full Text] [Related]
16. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial. Eitel I, Wöhrle J, Suenkel H, Meissner J, Kerber S, Lauer B, Pauschinger M, Birkemeyer R, Axthelm C, Zimmermann R, Neuhaus P, Brosteanu O, de Waha S, Desch S, Gutberlet M, Schuler G, Thiele H. J Am Coll Cardiol; 2013 Apr 02; 61(13):1447-54. PubMed ID: 23466078 [Abstract] [Full Text] [Related]